<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Patients with Fanconi <z:hpo ids='HP_0001903'>Anemia</z:hpo> (FANC) have a well documented increased risk to develop <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, especially <z:hpo ids='HP_0004808'>Acute Myeloid Leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:hpo ids='HP_0002863'>Myelodysplastic Syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The risk for heterozygous individuals is not clear, epidemiological data are inconsistent </plain></SENT>
<SENT sid="2" pm="."><plain>If the risk for heterozygous individuals to develop <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> was increased, they should be found in groups of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> at higher proportion than in the <z:mpath ids='MPATH_458'>normal</z:mpath> population </plain></SENT>
<SENT sid="3" pm="."><plain>We are currently screening a pediatric population with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> for mutations in the FANCA, FANCC and FANCG gene, and report here on siblings carrying a heterozygous frameshift mutation in the FANCC Gene </plain></SENT>
<SENT sid="4" pm="."><plain>PATIENTS AND METHODS: Using PCR based single strand conformational analysis we screened the DNA from pediatric patients suffering from 1 degree or 2 degrees <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> for mutations in the FANCA (43 exons), FANCC (14 exons) and FANCG (14 exons) gene, and included one patient with refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e>, being the brother of a patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> transforming into <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Aberrant PCR products were directly sequenced </plain></SENT>
<SENT sid="6" pm="."><plain>Flowcytometric measurement of <z:chebi fb="0" ids="52290">mitogen</z:chebi>-sensitivity and G2-phase arrest is used to evaluate cultured stimulated lymphocytes from individuals carrying FANC-mutations </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: A novel heterozygous frame-shift mutation, 377-378delGA in the FANCC gene was found in 2 siblings, both suffering from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> with subsequent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> transforming to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in one of them </plain></SENT>
<SENT sid="8" pm="."><plain>No other mutation was found by direct sequencing of the complete FANCC gene </plain></SENT>
<SENT sid="9" pm="."><plain>Both patients died under therapy </plain></SENT>
<SENT sid="10" pm="."><plain>The parents (first degree cousins) and one healthy brother are also carriers </plain></SENT>
<SENT sid="11" pm="."><plain>Their lymphocytes show a higher <z:chebi fb="1" ids="25435">mutagen</z:chebi> sensitivity than <z:mpath ids='MPATH_458'>normal</z:mpath>, but do not get blocked in G2 phase as being typical for Fanconi <z:hpo ids='HP_0001903'>Anemia</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: As the mutation causes a premature Stopcodon within exon 4 of the FANCC gene it has to be regarded as a causal FANCC gene defect </plain></SENT>
<SENT sid="13" pm="."><plain>The findings within this family support the hypothesis of an increased risk to develop <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> in heterozygous carriers of FANC-mutations </plain></SENT>
<SENT sid="14" pm="."><plain>A systematic screening of further patients is needed, and we are currently examining a larger cohort to get a better estimate of the true risk of heterozygosity </plain></SENT>
</text></document>